Literatur
- 1
Jolly F.
Über Myasthenia gravis pseudoparalytica.
Berl Klin Wschr.
1895;
32
1-7
- 2
Phillips L H.
The epidemiology of myasthenia gravis.
Neurol Clin.
1994;
12
263-271
- 3
Thomas C R, Wright C D, Loehrer P J.
Thymoma: state of the art.
J Clin Oncol.
1999;
17
2280-2289
- 4 Köhler W, Sieb J P. Myasthenia gravis. Bremen; UNI-MED Verlag 2000
- 5 Brandt T, Dichgans J, Diener H C. Therapie und Verlauf neurologischer Erkrankungen. Stuttgart,
Berlin, Köln, Mainz; Kohlhammer Verlag 2002
- 6
Papazian O.
Transient neonatal myasthenia gravis.
J Child Neurol.
1992;
7
135-141
- 7
Toyka K V, Drachman D B, Pestronk A, Kao I, Fischbeck K H.
Myasthenia gravis: passive transfer from man to mouse.
Science.
1975;
190
397-399
- 8 Bufler J, Franke C.
Myopathien und neuromuskuläre Übertragungsstörungen. In: Klinische Neurobiologie. Heidelberg, Berlin, Oxford; Spektrum Akademischer Verlag
1997
- 9
Vincent A, Bowen J, Newsom-Davis J, McConville J.
Seronegative generalised myasthenia gravis: clinical features, antibodies and their
targets.
Lancet Neurol.
2003;
2
99-106
- 10
Hoch W, McConville J, Helms S, Melms A, Vincent A.
Autoantibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis
without acetylcholine receptor antibodies.
Nat Med.
2001;
7
365-368
- 11
Romi F, Skeie G O, Aarli J A, Gilhus N E.
Muscle autoantibodies in subgroups of myasthenia gravis patients.
J Neurol.
2000;
247
369-375
- 12
Besinger U A, Toyka K V, Heininger K, Fateh-Moghadam A, Schumm F, Sandel P.
Long-term correlation of clinical coursde and acetylcholine receptor antibody in patients
with myasthenia gravis.
Ann N Y Acad Sci.
1981;
377
812-814
- 13 Dengler R.
Repetitive Nervenstimulation. In: Bischoff C, Dengler R, Hopf HC EMG NLG. Stuttgart, New York; Thieme Verlag 2003
- 14
Palace J, Newsom-Davis J, Lecky B.
A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia
gravis. Myasthenia gravis study group.
Neurology.
1998;
50
1778-1783
- 15
Tindall R S, Rollins J A, Phillips J P, Greenlee R G, Wells L, Belendiuk G.
Preliminary results of a double-blind, randomized, placebo-controlled trial of ciclosporin
in myasthenia gravis.
N Engl J Med.
1987;
316
719-724
- 16
Chaudhry V, Cornblath D R, Griffin J W, O'Brian R, Drachman D B.
Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases.
Neurology.
2001;
29
94-96
- 17
de Feo L G, Schottlender J, Martelli N A, Molfino N A.
Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis.
Muscle Nerve.
2002;
26
31-36
- 18
Gajdos P, Chevret S, Clair B, Trachant C, Chastang C.
Clinical trial of plasma exchange and high dose intravenous immunoglobulin in myasthenia
gravis. Myasthenia gravis clinical study group.
Ann Neurol.
1997;
41
789-796
- 19
Gajdos P, Chevret S, Toyka K V.
Intravenous immunoglobulin for myasthenia gravis.
Chochrane Database Syst Rev.
2006;
19 (2)
- 20
Lanska D J.
Indications for thymektomie in myasthenia gravis.
Neurology.
1990;
40
1828-1829
- 21
Lennon V A, Kryzer T J, Griesmann G E, O'Suilleabhain P E, Windebank A J, Woppmann A.
Calcium channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic
syndromes.
N Engl J Med.
1995;
332
1467-1474
- 22
McEvoy K M, Windebank A J, Daube R, Low P A.
3.4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome.
N Engl J Med.
1989;
321
1567-1571
- 23
Engel A G, Sine S M.
Current understanding of congenital myasthenic syndromes.
Curr Opin Pharmacol.
2005;
5
308-321
Prof. Dr. med. Johannes Bufler
Neurologische Klinik des Inn-Salzach-Klinikums
Gabersee Haus 60
83512 Wasserburg am Inn
Email: Johannes.Bufler@gabersee.de
